Updated NETs Clinical Trials
Studies found on ClinicalTrials.gov by a search of: Other terms: neuroendocrine NOT Melanoma NOT PMS | Last update posted in the last 30 days
-
Observational Study on GEP-and Pulm-NET Treated at FPG
Conditions: Neuroendocrine Tumors; Gep Net; Pulmonary Neuroendocrine Neoplasm Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting -
PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC
Conditions: Neuroendocrine Carcinoma Sponsors: European Institute of Oncology Recruiting -
A Clinical Study to Evaluate the Safety and Efficacy of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
Conditions: Advanced Neuroendocrine Neoplasm Interventions: Drug: Lutetium[177Lu] Oxodotreotide Injection Sponsors: Sinotau Pharmaceutical Group Not yet recruiting -
177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry
Conditions: Neuroendocrine Tumors; Neuroendocrine Tumor Grade 1; Neuroendocrine Tumor Grade 2 Interventions: Drug: Lutetium Lu 177 dotatate therapy Sponsors: University of Iowa; Novartis Not yet recruiting -
FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum
Conditions: Large Cell Neuroendocrine Carcinoma of the Lung Interventions: Drug: Durvalumab with etoposide and Carboplatin/Cisplatin Sponsors: Centre Leon Berard; Groupe Français de Pneumo-Cancérologie Not yet recruiting -
Mechanisms Underlying Antidepressant Effects of Physical Activity
Conditions: Depression Interventions: Other: Aerobic exercise; Other: Stretching and relaxation Sponsors: University College, London; King's College London; Queen Mary University of London; University of Dublin, Trinity College Not yet recruiting -
SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma
Conditions: Recurrent/Refractory Small Cell Lung Cancer Lung Large Cell Neuroendocrine Carcinoma Interventions: Drug: SNC115 injection Sponsors: Shanghai Simnova Biotechnology Co.,Ltd.; Shanghai Chest Hospital Recruiting -
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Conditions: Metastatic Neuroendocrine Prostate Cancer Interventions: Drug: [68Ga]Ga-PSMA-11; Drug: [68Ga]GA-DOTA-TATE; Drug: [68Ga]Ga-NeoB; Drug: [177Lu]Lu-PSMA-617; Drug: [177Lu]Lu-DOTA-TATE; Drug: [177Lu]Lu-NeoB; Drug: L-Lysine HCl-L-Arginine HCl, 2.5 %,; Drug: Gonadotropin-releasing hormone (GnRH) analogues; Drug: GnRH antagonists; Drug: Antiemetics & antinauseants; Drug: Metoclopramide Sponsors: Novartis Pharmaceuticals Not yet recruiting -
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
Conditions: Genetic Predisposition; Paraganglioma; Pheochromocytoma; ALS; Parkinson Disease; Polyneuropathies; Frontotemporal Dementia; Alzheimer Disease; Cardiomyopathy Non-ischemic; Thoracic Aortic Aneurysm Interventions: Behavioral: Behavioral nudge Sponsors: University of Pennsylvania Not yet recruiting -
Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
Conditions: Neuroendocrine Carcinoma Interventions: Biological: ZG005; Drug: Etoposide; Drug: Cisplatin; Drug: Placebo Sponsors: Suzhou Zelgen Biopharmaceuticals Co.,Ltd Not yet recruiting -
Ex-vivo Ultrasound Guided Radiofrequency Ablation on Pancreatic Solid Lesions
Conditions: Pancreatic Cancer; Endoscopic Ultrasound; Radiofrequency Ablation Interventions: Procedure: ex-vivo RFA under US control at 10 Watts (W) of power in 3 differents arms of lesions; Procedure: ex-vivo RFA under US control at 30 Watts (W) of power in 3 differents arms of lesions; Procedure: ex-vivo RFA under US control at 50 Watts (W) of power in 3 differents arms of lesions Sponsors: IRCCS San Raffaele Terminated -
Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
Conditions: Neuroendocrine Carcinoma; Non-small Cell Lung Cancer; Histology Transformation Sponsors: Fudan University Recruiting -
Chemotherapy Followed by Response-Based Reduced Radiation Therapy for Patients With Central Nervous System Germinomas
Conditions: Intracranial Germ Cell Tumor; Childhood Central Nervous System Germinoma Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy; Drug: Carboplatin; Drug: Etoposide; Radiation: Intensity-Modulated Radiation Therapy Sponsors: Children's Oncology Group Not yet recruiting -
The Effect of Ketone Ester Supplementation and Ketogenic Diet on Brain Plasticity in Overweight/Obese Adults
Conditions: Overweight and Obesity; Cognitive Change; Psychophysiologic Reaction Interventions: Dietary Supplement: Ketone Monoester Supplementation; Dietary Supplement: Ketogenic diet Sponsors: University of Macau Not yet recruiting -
Dopamine, Reward Learning and Sex Hormones
Conditions: Hormonal Changes; Menstrual Cycle Interventions: Drug: Levodopa administration; Drug: Placebo administration Sponsors: University Hospital Tuebingen; German Research Foundation; Uppsala University Not yet recruiting -
The Role of 68GA DOTATATE PET/CT In Breast Cancer Imaging
Conditions: Breast Cancer Interventions: Diagnostic Test: 18F FDG PET/CT; Diagnostic Test: 68Ga DOTATATE PET/CT Sponsors: Celal Bayar University Completed -
Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs
Conditions: Neuroendocrine Tumors; GEP-NET Sponsors: IRCCS San Raffaele Active, not recruiting -
EchoTip AcuCore Post-Market Clinical Study
Conditions: Adenocarcinoma; Neuroendocrine Tumors; Hepatocellular Carcinoma; Cholangiocarcinoma; Malignant Lymphoma; Metastasis; Chronic Pancreatitis; Autoimmune Pancreatitis Interventions: Device: EchoTip AcuCore Sponsors: Cook Research Incorporated Not yet recruiting -
Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients
Conditions: Neuroendocrine Neoplasm Sponsors: European Institute of Oncology Recruiting -
Clinical Application of the J-PET Scanner Prototype
Conditions: Prostate Cancer; Prostatic Hyperplasia; Prostatic Neoplasms; Prostate Cancer Metastatic; Neuroendocrine Tumors; Neuroendocrine Carcinoma Interventions: Diagnostic Test: J-PET scan Sponsors: Jagiellonian University; University Hospital in Krakow Recruiting -
A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan
Conditions: Neuroendocrine Neoplasms Interventions: Drug: [68Ga]Ga-DOTA-TATE; Drug: 68Ge/68Ga Generator Sponsors: Novartis Pharmaceuticals; Eckert & Ziegler Radiopharma GmbH Recruiting -
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Conditions: Small Cell Carcinoma of the Bladder; High Grade Neuroendocrine Tumors of the Urinary Tract Interventions: Drug: Lurbinectedin; Drug: Avelumab Sponsors: National Cancer Institute (NCI) Recruiting -
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors
Conditions: Digestive System Neuroendocrine Neoplasm; Lung Neuroendocrine Neoplasm; Malignant Solid Neoplasm; Pancreatic Neuroendocrine Neoplasm Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Incomplete Freund''s Adjuvant; Procedure: Magnetic Resonance Imaging; Biological: Sargramostim; Biological: SVN53-67/M57-KLH Peptide Vaccine; Drug: Temozolomide Sponsors: Roswell Park Cancer Institute Not yet recruiting -
Self-Care Training for Family Caregivers of Persons With Neurodegeneration
Conditions: Caregiver Burden; Caregiver Stress Interventions: Other: Mindfulness Meditation; Other: Psychoeducation; Other: Wait list control Sponsors: Toronto Metropolitan University Recruiting -
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer
Conditions: Small Cell Carcinoma of the Bladder; Small Cell Carcinoma of the Urinary Tract; Squamous Cell Carcinoma of the Bladder; Squamous Cell Carcinoma of the Urinary Tract; Primary Adenocarcinoma of the Bladder; Primary Adenocarcinoma of the Urinary Tract; Renal Medullary Carcinoma; Squamous Cell Carcinoma of the Penis Interventions: Drug: Sacituzumab govitecan; Drug: Atezolizumab Sponsors: National Cancer Institute (NCI) Not yet recruiting -
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors; Neuroendocrine Tumor of the Lung; Neuroendocrine Tumor Grade 1; Neuroendocrine Tumor Grade 2; Neuroendocrine Tumor of Pancreas Interventions: Drug: [212Pb] VMT-α-NET; Diagnostic Test: [203Pb] VMT-α-NET SPECT/CT Sponsors: David Bushnell; Holden Comprehensive Cancer Center; National Cancer Institute (NCI); Perspective Therapeutics Active, not recruiting -
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
Conditions: Neuroendocrine Neoplasms Interventions: Drug: BI 764532; Drug: Carboplatin; Drug: Etoposide; Drug: Cisplatin Sponsors: Boehringer Ingelheim Recruiting -
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors; Somatostatin Receptor-positive Neuroendocrine Tumor Interventions: Device: Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT); Device: Photon Emission Tomography / CT (PET/CT); Drug: 64Cu-Dotatate; Drug: 177Lu-Dotatate Sponsors: University of Wisconsin, Madison Not yet recruiting -
Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
Conditions: Neuroendocrine Carcinomas; Neuroendocrine Tumors; Carcinoma, Neuroendocrine; Carcinoma, Adrenocortical; Carcinoma, Adrenal Cortical Interventions: Drug: ADCT-701 Sponsors: National Cancer Institute (NCI) Recruiting -
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
Conditions: Pancreatic Adenocarcinoma; Adenosquamous Carcinoma; Pancreatic Neuroendocrine Tumor; Pancreatic Neuroendocrine Carcinoma; Gastrointestinal Neuroendocrine Tumor; Gastrointestinal Neuroendocrine Carcinoma; Neuroendocrine Prostate Carcinoma Interventions: Drug: ESK981 Sponsors: University of Michigan Rogel Cancer Center Recruiting -
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Conditions: Advanced Solid Tumors Interventions: Drug: INCB099280; Drug: axitinib Sponsors: Incyte Corporation Recruiting -
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
Conditions: Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8; Locally Advanced Merkel Cell Carcinoma; Metastatic Merkel Cell Carcinoma; Refractory Merkel Cell Carcinoma; Unresectable Merkel Cell Carcinoma Interventions: Drug: Avelumab; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Drug: Tuvusertib Sponsors: National Cancer Institute (NCI) Recruiting -
The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia
Conditions: Lung Cancer Interventions: Drug: Pioglitazone 45 mg; Drug: Placebo Sponsors: Pennington Biomedical Research Center Recruiting -
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Conditions: Small Cell Lung Carcinoma; Neuroendocrine Neoplasms Interventions: Drug: BI 764532, formulation 1; Drug: BI 764532, formulation 2 Sponsors: Boehringer Ingelheim Recruiting -
A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
Conditions: Small Cell Lung Carcinoma (SCLC); Neuroendocrine Neoplasms Interventions: Drug: BI 764532; Drug: Ezabenlimab Sponsors: Boehringer Ingelheim Recruiting -
LUTATHERA Injection General Use Result Survey
Conditions: Somatostatin Receptor-positive Neuroendocrine Tumor Interventions: Other: LUTATHERA Sponsors: Novartis Pharmaceuticals Active, not recruiting -
Vestibular Schwannoma Organoids
Conditions: Vestibular Schwannoma Sponsors: Maastricht Radiation Oncology; Maastricht University Medical Center Recruiting -
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial
Conditions: Metastatic Midgut Neuroendocrine Tumor; Metastatic Midgut Neuroendocrine Tumor G1; Metastatic Midgut Neuroendocrine Tumor G2; Unresectable Midgut Neuroendocrine Tumor Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Everolimus; Drug: Lutetium Lu 177 Dotatate; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: National Cancer Institute (NCI) Recruiting -
Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms
Conditions: Pancreatic Neuroendocrine Neoplasm Interventions: Diagnostic Test: Hereditary Cancer Panel Sponsors: University of California, San Francisco; University of California Pancreatic Cancer Consortium (UCPCC) Recruiting -
Genetics of Appendix Cancer Study
Conditions: Appendix Cancer; Appendiceal Cancer; Appendiceal Neoplasms; Appendiceal Mucinous Neoplasm; Appendiceal Adenocarcinoma; Appendiceal Carcinoid Tumor; Appendiceal Neoplasm Malignant Secondary; Appendix Adenocarcinoma; Appendix Mucinous Neoplasm; Appendix Tumor; Appendix Cancer Metastatic; Appendix NET; Low-Grade Appendix Mucinous Neoplasm; High Grade Appendix Mucinous Neoplasm; High Grade Appendix Mucinous Adenocarcinoma Interventions: Genetic: Genetic profiling; Other: Retrospective tissue procurement Sponsors: Andreana Holowatyj, PhD, MSCI Recruiting -
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
Conditions: Metastatic Neuroendocrine Tumor Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Lutetium Lu 177 Dotatate; Procedure: Magnetic Resonance Imaging; Drug: Triapine Sponsors: National Cancer Institute (NCI) Recruiting -
The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma
Conditions: Pheochromocytoma; Paraganglioma; Adrenalectomy; Status; Adrenergics Causing Adverse Effects in Therapeutic Use Interventions: Drug: Phenoxybenzamine Sponsors: Seoul National University Hospital Recruiting -
A Study of EBC-129 in Advanced Solid Tumours
Conditions: Advanced Solid Tumours Interventions: Drug: EBC-129; Drug: Pembrolizumab Sponsors: EDDC (Experimental Drug Development Centre), A*STAR Research Entities; Parexel Recruiting -
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
Conditions: Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation; Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Small Cell Neuroendocrine Carcinoma; Stage IV Prostate Cancer AJCC v8 Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Radiation: Gallium Ga 68-DOTATATE; Drug: Lutetium Lu 177 Dotatate; Procedure: Positron Emission Tomography Sponsors: National Cancer Institute (NCI) Recruiting -
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
Conditions: Metastatic Pancreatic Neuroendocrine Tumor; Pancreatic Neoplasm; Stage III Pancreatic Neuroendocrine Tumor AJCC v8; Stage IV Pancreatic Neuroendocrine Tumor AJCC v8; Unresectable Pancreatic Neuroendocrine Tumor Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Lutetium Lu 177 Dotatate; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Drug: Sunitinib Malate Sponsors: National Cancer Institute (NCI) Recruiting -
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
Conditions: Small Cell Lung Cancer; Neuroendocrine Carcinoma Interventions: Drug: RO7616789; Drug: Tocilizumab Sponsors: Hoffmann-La Roche Recruiting -
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
Conditions: Advanced Solid Tumors Interventions: Drug: ABBV-706; Drug: Cisplatin; Drug: Budigalimab; Drug: Carboplatin Sponsors: AbbVie Recruiting -
Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery
Conditions: Merkel Cell Carcinoma Interventions: Drug: Retifanlimab; Drug: Cisplatin; Drug: Etoposide Sponsors: Gruppo Oncologico del Nord-Ovest Recruiting -
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
Conditions: Merkel Cell Carcinoma Interventions: Drug: Pembrolizumab; Drug: Lutetium Lu 177 dotatate Sponsors: Weill Medical College of Cornell University Recruiting -
Study of Oral MRT-2359 in Selected Cancer Patients
Conditions: NSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC With High or Low L-MYC or N-MYC Expression; HR-positive, HER2-negative Breast Cancer; Prostate Cancer Interventions: Drug: Oral MRT-2359; Drug: Oral MRT-2359; Drug: Oral MRT-2359; Drug: Oral MRT-2359; Drug: Oral MRT-2359; Drug: Oral MRT-2359 Sponsors: Monte Rosa Therapeutics, Inc Recruiting